Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  DBV Technologies    DBV   FR0010417345

DBV TECHNOLOGIES

(DBV)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
07/07/2020 07/08/2020 07/09/2020 07/10/2020 07/13/2020 Date
8.145(c) 7.9(c) 7.55(c) 7.525(c) 7.615 Last
286 939 216 080 374 667 473 637 155 221 Volume
+0.56% -3.01% -4.43% -0.33% +1.20% Change
More quotes
Financials
Sales 2020 14,3 M 16,2 M 16,2 M
Net income 2020 -172 M -195 M -195 M
Net cash position 2020 138 M 156 M 156 M
P/E ratio 2020 -2,07x
Yield 2020 -
Sales 2021 56,1 M 63,5 M 63,5 M
Net income 2021 -139 M -158 M -158 M
Net cash position 2021 44,7 M 50,6 M 50,6 M
P/E ratio 2021 -2,52x
Yield 2021 -
Capitalization 413 M 467 M 468 M
EV / Sales 2020 19,3x
EV / Sales 2021 6,57x
Nbr of Employees 311
Free-Float 76,5%
More Financials
Company
DBV Technologies specializes in developing solutions for diagnosing and treating food allergies (primarily to peanuts and cow's milk) using a patch (Viaskin®) that administers active ingredients into the top layers of the skin. 
More about the company
Surperformance© ratings of DBV Technologies
Trading Rating : Investor Rating :
More Ratings
Latest news on DBV TECHNOLOGIES
07/10DBV Technologies Announces Publication of PEOPLE Phase III Open-Label Extensi..
GL
06/29DBV TECHNOLOGIES : Provides Operational and Business Update
AQ
06/26DBV Technologies Provides Operational and Business Update
GL
06/04DBV Technologies to Present Data on Epicutaneous Immunotherapy and Food Aller..
GL
06/02DBV TECHNOLOGIES : To Present at the Goldman Sachs 41st Annual Global Healthcare..
GL
04/30DBV TECHNOLOGIES : Reports March 31, 2020 Cash Position
GL
04/30DBV TECHNOLOGIES : 1st quarter earnings
CO
04/20DBV Technologies Announces Results of its 2020 Ordinary and Extraordinary Gen..
GL
04/20DBV TECHNOLOGIES : Proxy Statments
CO
04/16DBV TECHNOLOGIES : - Ordinary and Extraordinary General Meeting of April 20, 202..
AQ
04/15DBV TECHNOLOGIES : Ordinary and Extraordinary General Meeting of April 20, 2020
PU
04/13DBV TECHNOLOGIES : - Ordinary and Extraordinary General Meeting of April 20, 202..
AQ
04/10Ordinary and Extraordinary General Meeting of April 20, 2020 to be Held in Cl..
GL
03/31DBV TECHNOLOGIES : - Ordinary and Extraordinary General Meeting of April 20, 202..
AQ
03/30Ordinary and Extraordinary General Meeting of April 20, 2020
GL
More news
News in other languages on DBV TECHNOLOGIES
07/10DBV Technologies Announces Publication of PEOPLE Phase III Open-Label Extensi..
07/10DBV TECHNOLOGIES : annonce la publication dans le Journal of Allergy and Clinica..
06/29DBV TECHNOLOGIES : Provides Operational and Business Update
06/26STOCK MARKET PARIS : Paris toujours marquée par l'incertitude
06/26DBV TECHNOLOGIES s'inflige une cure d'austérité de mauvaise augure
More news
Chart DBV TECHNOLOGIES
Duration : Period :
DBV Technologies Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DBV TECHNOLOGIES
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 18,27 €
Last Close Price 7,53 €
Spread / Highest target 308%
Spread / Average Target 143%
Spread / Lowest Target 15,6%
EPS Revisions
Managers
NameTitle
Daniel Tassé Chief Executive Officer & Executive Director
Michel de Rosen Non-Executive Chairman
Ramzi Benamar Chief Financial Officer
Bertrand Dupont Chief Technology Officer
Hugh A. Sampson Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
DBV TECHNOLOGIES-61.67%467
JOHNSON & JOHNSON-2.40%375 087
ROCHE HOLDING AG5.75%300 427
MERCK & CO., INC.-15.64%193 674
NOVARTIS AG-10.77%192 177
PFIZER, INC.-13.65%187 920